Method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen

A method of treating a patient with late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency caused by a mutation in the CYP21A2 gene comprising:

• administering, to the patient, daily doses of glucocorticoids comprising:
• a dose of a short-acting glucocorticoid comprising hydrocortisone in the morning;
• and
• a dose of a long-acting glucocorticoid comprising dexamethasone in the evening,
• wherein the doses are optimized for the patient to counterbalance adverse reactions;
• measuring a serum level of sex hormone binding globulin (SHBG) of the patient;
• and
• adjusting the daily doses of the glucocorticoids based on the measured serum level of SHBG, wherein said adjusting comprises:
• decreasing the dose of the long-acting glucocorticoid if the serum level of SHBG has reached a level of less than 120 nmol/L for women, or less than 49 nmol/L for men under 50 years of age, or less than 70 nmol/L for men over 50 years of age, otherwise the daily dose of dexamethasone is increased.